173 publications

Name Date Type Actions

Availability of the 2021 Universal Registration Document

Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022.

 		Public releases

Q1 2022 SALES: €135M

Q1 2022 SALES: €135M
(UP 5.5% AS REPORTED, UP 2.2% AT CONSTANT EXCHANGE RATES)
Q1 2022 ESSENTIALS SALES: €77M
(UP 8.1% AS REPORTED, UP 5.5 AT CONSTANT EXCHANGE RATES)

 		Public releases

2021 Annual results

ALL FINANCIAL INDICATORS UP.
Annual sales: €521m (up 21.9% as reported).
Essentials sales: €296m (up 34.0% as reported).
EBIT before depreciation of acquired assets: €101m (up 54.5%).
Net income - Group share: €63m (up 226.9%).

 		Public releases

Double-digit growth in 2021

Total Group Sales: €521 million (up 21.9% as reported)
Annual Sale of Essential products: €296 million (up 34.0% as reported)

 		Public releases

Third quarter revenues: €132 million

 		Public releases

2021 first half results

2021 Half year results

 		Public releases

Availability of the 2020 universal registration document

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

 		Public releases

Q1 2021 sales

Q1 2021 sales : €128M (up 28% at constant exchange rates, up 24% as reported)
Q1 2021 essential sales : €72.6M (up 38% at constant exchange rates, up 36% as reported)

 		Public releases

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m

 		Public releases

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

 		Public releases